ADRB2 rs1042712: Metabolic and Vascular Influence
The rs1042712 single nucleotide polymorphism is a common variation located in the ADRB2 gene, which codes for the beta-2 adrenergic receptor. Research associates this variant with modest differences in metabolic rate, lipolytic activity, and cardiovascular reactivity to catecholamines. However, the evidence supporting these physiological associations remains limited and frequently context-dependent.
What each genotype means
Increased agonist sensitivity
This genotype is often referred to as the Arg16 homozygous state. Research suggests individuals with this profile may exhibit increased sensitivity to beta-agonist medications, though responses can vary significantly and may decrease with regular use. Please discuss any medication dosing or treatment responses with your clinician or pharmacist.
This genotype is common globally, though its prevalence varies significantly across different ancestral populations.
Heterozygous receptor profile
This genotype represents a mix of the Arg16 and Gly16 alleles. Studies on this variant indicate that metabolic and cardiovascular responses to adrenergic stimulation can be complex and are not consistently linked to specific health outcomes in all populations. Please consult with your healthcare provider regarding any concerns about medication efficacy or metabolic health.
This is a very common genotype found in a large proportion of the global population.
Standard receptor response
This genotype is often referred to as the Gly16 homozygous state. Some studies have associated this profile with different metabolic responses to epinephrine compared to the Arg16 variant, though findings regarding obesity and cardiovascular traits remain inconsistent across large-scale studies. Please discuss any specific health or medication concerns with your clinician.
This genotype is frequently observed across diverse human populations, occurring at a similar frequency to the AA genotype in many groups.
Genomic Context and Variant Architecture
The single nucleotide polymorphism rs1042712 is located on human chromosome 5 within the ADRB2 locus. As cataloged in resources such as [dbSNP rs1042712](https://www.ncbi.nlm.nih.gov/snp/rs1042712) and [Ensembl ADRB2 Overview](https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000169252), ADRB2 is an intronless gene that encodes a G-protein-coupled receptor responsive to endogenous catecholamines. Genomic variants within this region often display tight linkage disequilibrium with neighboring functional variations, such as rs1042713 (Arg16Gly) and rs1042714 (Gln27Glu). Because of this genetic co-inheritance, molecular analyses often evaluate these variations within broader haplotypic contexts rather than in absolute isolation.
Biological Role of the ADRB2 Receptor
The beta-2 adrenergic receptor is expressed in diverse human tissues, playing pivotal roles across pulmonary, vascular, and metabolic physiology as reviewed in the [ADRB2 Very Important Pharmacogene Summary](https://pmc.ncbi.nlm.nih.gov/articles/PMC3098753/). Upon activation by catecholamines like epinephrine, ADRB2 stimulates intracellular adenylyl cyclase, driving cyclic AMP (cAMP) production. In adipose tissue, this cascade activates hormone-sensitive lipase, stimulating lipolysis and mobilizing stored fatty acids. In vascular smooth muscle, it facilitates vasodilation and moderates systemic vascular tone during periods of physical exertion or sympathetic stress.
Current Scientific Evidence and Phenotypic Links
Studies documented in sources like [OMIM Entry 109690](https://omim.org/entry/109690) and the [GWAS Catalog](https://www.ebi.ac.uk/gwas/search?query=ADRB2) have investigated ADRB2 variants for their association with resting metabolic rate, body composition, lipid mobilization, and hemodynamic responses. While some observational cohorts have suggested that specific alleles modulate lipolytic responsiveness and blood pressure reactivity, results across broader multi-ancestry meta-analyses have yielded mixed conclusions. As cataloged in public genetic repositories, the clinical and phenotypic evidence linking rs1042712 directly to metabolic outcomes remains classified as limited and should be viewed as an exploratory statistical correlation rather than a definitive causal mechanism.
Population Distribution and Haplotype Frequency
Variant alleles at the rs1042712 locus are widely prevalent across diverse global ancestries. Epidemiological surveys and population databases record a minor allele frequency typically ranging between 0.35 and 0.45 in general cohorts. Because ADRB2 polymorphisms vary notably among continental groups, background linkage structures differ, meaning that a single nucleotide finding may coincide with different downstream functional haplotypes depending on an individual's ancestral background.
Interpreting Results: What This Means for You
Information about rs1042712 provides insight into subtle inherited predispositions related to adrenergic receptor signaling, but it is not diagnostic for any disease. This variant does not cause cardiovascular disease, metabolic syndrome, or respiratory conditions on its own. Major lifestyle factors—including nutritional patterns, physical conditioning, and chronic stress management—exert a vastly stronger influence on metabolic health and cardiovascular tone than individual ADRB2 polymorphisms. Additionally, consumers reviewing adrenergic pharmacogenomic data should never alter prescribed medications, such as bronchodilators or beta-blockers, without direct guidance from a qualified physician or pharmacist.
How common is this variant?
The rs1042712 variant is common globally, exhibiting a minor allele frequency between approximately 0.35 and 0.45 across diverse human ancestral populations.
Frequently asked questions
Does my rs1042712 genotype mean I have a slow metabolism?
No. While ADRB2 participates in sympathetic regulation of metabolic rate and fat breakdown, rs1042712 alone exerts only a minor statistical influence. Overall metabolic health is predominantly determined by diet, sleep, lean muscle mass, and daily activity.
Can this genetic variant cause heart disease or high blood pressure?
No single common variant like rs1042712 causes cardiovascular disease. The variant has been explored in association with transient vascular reactivity to stress, but it is not a validated standalone diagnostic marker for hypertension.
Does rs1042712 affect how I should take beta-blockers or inhalers?
While the ADRB2 gene is critical for adrenergic signaling, you should never adjust prescription medications based on commercial genetic test results. Always consult your prescribing physician or pharmacist before modifying any treatment regimen.
Why do some scientific studies on ADRB2 show contradictory results?
The ADRB2 locus is composed of multiple tightly linked variants that often function together as haplotypes rather than isolated markers. Differences in study size, participant ancestry, and environmental factors frequently lead to variable results across scientific literature.
Sources & further reading
Educational information only, last refreshed 9/6/2026. Not medical advice — these associations describe population statistics, not individual predictions.
Curious what your genotype is for rs1042712?
Upload a raw DNA file from 23andMe, AncestryDNA, MyHeritage, or FamilyTreeDNA and see this variant — plus thousands more — interpreted in your full report.
Get my report — $29Related variants in ADRB2
Variant in the beta-2 adrenergic receptor linked to metabolic regulation, exercise-induced lipolysis, and endurance performance.
Synonymous polymorphism in the beta-2 adrenergic receptor (Gln27Glu) modulating receptor down-regulation.
The Gln27Glu variant in the beta-2 adrenergic receptor is associated with metabolic and vascular responses to exercise.
Modulates beta-2 adrenergic receptor expression and cardiovascular reactivity.
This variant in the beta-2 adrenergic receptor gene is associated with differential responses to beta-agonist therapy in asthma patients.
This variant in the beta-2 adrenergic receptor gene is associated with altered responses to asthma medications and bronchodilators.